CytomX Therapeutics - CTMX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.53
  • Forecasted Upside: 273.14%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.75
▼ -0.08 (-4.37%)

This chart shows the closing price for CTMX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CytomX Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTMX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTMX

Analyst Price Target is $6.53
▲ +273.14% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for CytomX Therapeutics in the last 3 months. The average price target is $6.53, with a high forecast of $8.00 and a low forecast of $3.59. The average price target represents a 273.14% upside from the last price of $1.75.

This chart shows the closing price for CTMX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in CytomX Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2024BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$3.25 ➝ $3.59Low
5/9/2024HC WainwrightReiterated RatingNeutralLow
5/9/2024WedbushUpgradeNeutral ➝ Outperform$3.00 ➝ $8.00Low
5/6/2024Jefferies Financial GroupUpgradeHold ➝ Buy$2.50 ➝ $8.00Low
5/1/2024BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$3.25Low
4/22/2024JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralLow
11/8/2023WedbushUpgradeNeutral ➝ Outperform$2.00 ➝ $3.00Low
8/9/2023BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$3.15 ➝ $3.19Low
8/9/2023WedbushReiterated RatingNeutral$2.00Low
3/28/2023WedbushReiterated RatingNeutral$2.00Low
3/28/2023MizuhoLower TargetNeutral$4.00 ➝ $2.00Low
1/6/2023BMO Capital MarketsBoost TargetMarket Perform$2.60 ➝ $3.20Low
11/14/2022BMO Capital MarketsDowngradeOutperform ➝ Market Perform$3.00 ➝ $2.60Low
11/10/2022JPMorgan Chase & Co.DowngradeOverweight ➝ UnderweightN/A
11/9/2022WedbushReiterated RatingNeutral$2.00Low
7/19/2022CowenDowngradeMarket PerformLow
7/11/2022CowenDowngradeOutperform ➝ Market PerformN/A
7/11/2022CowenDowngradeOutperform ➝ Market PerformN/A
7/11/2022HC WainwrightDowngradeBuy ➝ NeutralN/A
7/7/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$12.00 ➝ $2.00N/A
7/7/2022BMO Capital MarketsLower TargetBuy$9.00 ➝ $3.00N/A
7/7/2022BTIG ResearchLower TargetBuy$16.00 ➝ $8.00N/A
7/7/2022WedbushDowngradeOutperform ➝ Neutral$6.00 ➝ $2.00N/A
7/7/2022BarclaysLower TargetOverweight$7.00 ➝ $3.50N/A
7/7/2022MizuhoDowngradeBuy ➝ Neutral$16.00 ➝ $4.00N/A
7/7/2022Piper SandlerDowngradeOverweight ➝ Neutral$10.00 ➝ $1.50N/A
6/23/2022BMO Capital MarketsInitiated CoverageOutperform$9.00Low
5/27/2022Piper SandlerLower Target$16.00 ➝ $10.00Low
5/10/2022WedbushLower TargetOutperform$10.00 ➝ $6.00High
3/4/2022HC WainwrightReiterated RatingBuy$11.00Low
3/2/2022JPMorgan Chase & Co.Lower TargetOverweight$10.00 ➝ $9.00High
1/18/2022BarclaysUpgradeUnderweight ➝ Overweight$7.00High
12/22/2021HC WainwrightReiterated RatingBuy$12.00 ➝ $11.00High
11/15/2021BTIG ResearchInitiated CoverageBuy$16.00Medium
11/5/2021MizuhoReiterated RatingBuy$16.00High
8/9/2021HC WainwrightReiterated RatingBuy$12.00Medium
7/6/2021HC WainwrightReiterated RatingBuy$12.00Medium
5/28/2021BarclaysDowngradeEqual Weight ➝ Underweight$9.00 ➝ $7.00High
3/29/2021JPMorgan Chase & Co.Initiated CoverageOverweight$14.00High
3/23/2021Jefferies Financial GroupUpgradeHold ➝ BuyHigh
11/8/2020BarclaysReiterated RatingHold$9.00High
9/22/2020GuggenheimDowngradeBuy ➝ NeutralLow
9/15/2020CitigroupLower Target$11.00 ➝ $8.50Low
8/7/2020HC WainwrightReiterated RatingBuy$12.00Medium
6/1/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$16.00 ➝ $10.00High
5/29/2020MizuhoReiterated RatingBuy$16.00Low
5/17/2020NomuraReiterated RatingBuy$15.00High
5/14/2020HC WainwrightLower TargetBuy$16.00 ➝ $12.00High
5/10/2020NomuraReiterated RatingBuy$15.00Medium
5/8/2020HC WainwrightBoost TargetBuy$14.00 ➝ $16.00High
5/7/2020MizuhoReiterated RatingBuy$16.00High
4/29/2020MizuhoReiterated RatingBuy$16.00High
3/24/2020MizuhoReiterated RatingBuyLow
3/24/2020WedbushUpgradeNeutral ➝ OutperformLow
3/4/2020BarclaysInitiated CoverageEqual Weight$7.00Low
2/28/2020Nomura SecuritiesLower TargetBuy$22.00 ➝ $15.00High
2/24/2020HC WainwrightReiterated RatingBuy$14.00Low
12/20/2019HC WainwrightReiterated RatingBuy$14.00Medium
12/19/2019MizuhoInitiated CoverageBuy$16.00High
11/27/2019GuggenheimInitiated CoverageBuy$16.00Low
11/19/2019GuggenheimInitiated CoverageBuy$16.00High
11/11/2019WedbushDowngradeOutperform ➝ Neutral$25.00 ➝ $8.00High
8/12/2019MizuhoReiterated RatingBuy$16.00Medium
8/11/2019Nomura SecuritiesReiterated RatingBuy$22.00Medium
8/7/2019CowenReiterated RatingBuyHigh
7/29/2019MizuhoReiterated RatingBuy$16.00Low
6/12/2019MizuhoInitiated CoverageBuy ➝ Buy$16.00Medium
6/3/2019Cantor FitzgeraldReiterated RatingOverweight$21.00 ➝ $23.00High
(Data available from 5/27/2019 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/29/2023
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/28/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
12/28/2023
  • 7 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
1/27/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2024
  • 4 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/27/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/26/2024
  • 5 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
5/26/2024

Current Sentiment

  • 5 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
CytomX Therapeutics logo
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $1.75
Low: $1.75
High: $1.85

50 Day Range

MA: $2.25
Low: $1.59
High: $5.13

52 Week Range

Now: $1.75
Low: $1.04
High: $5.85

Volume

1,074,000 shs

Average Volume

4,287,280 shs

Market Capitalization

$136.36 million

P/E Ratio

8.75

Dividend Yield

N/A

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of CytomX Therapeutics?

The following Wall Street research analysts have issued research reports on CytomX Therapeutics in the last year: BMO Capital Markets, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., StockNews.com, and Wedbush.
View the latest analyst ratings for CTMX.

What is the current price target for CytomX Therapeutics?

3 Wall Street analysts have set twelve-month price targets for CytomX Therapeutics in the last year. Their average twelve-month price target is $6.53, suggesting a possible upside of 273.1%. Jefferies Financial Group Inc. has the highest price target set, predicting CTMX will reach $8.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $3.59 for CytomX Therapeutics in the next year.
View the latest price targets for CTMX.

What is the current consensus analyst rating for CytomX Therapeutics?

CytomX Therapeutics currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CTMX, but not buy more shares or sell existing shares.
View the latest ratings for CTMX.

What other companies compete with CytomX Therapeutics?

Other companies that are similar to CytomX Therapeutics include Cybin, Repare Therapeutics, I-Mab, Renovaro and Syros Pharmaceuticals. Learn More about companies similar to CytomX Therapeutics.

How do I contact CytomX Therapeutics' investor relations team?

CytomX Therapeutics' physical mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (605) 515-3185 and its investor relations email address is [email protected]. The official website for CytomX Therapeutics is www.cytomx.com. Learn More about contacing CytomX Therapeutics investor relations.